**MICRORNA AS MARKERS INVOLVED IN THE PROGRESSION OF CERVICAL CANCER**

**Authors Name**: Pushpendra D. Pratap1\* Syed Tasleem Raza1 Sharique Ahmad2

Affiliation

1\*Research Scholar, Department of Biochemistry, ERA’S Lucknow Medical College & Hospital, ERA University, Lucknow, Uttar Pradesh. India -226003.

1Professor , Department of Biochemistry, ERA’S Lucknow Medical College and Hospital, ERA University, Lucknow, Uttar Pradesh. India -226003.

2Professor, Department of Pathology, ERA’S Lucknow Medical College & Hospital, ERA University, Lucknow, Uttar Pradesh, India. -226003.

Corresponding author

Pushpendra D. Pratap

1\*Research Scholar, Department of Biochemistry, ERA’S Lucknow Medical College & Hospital, ERA University, Lucknow, Uttar Pradesh. India -226003.

Email Id: pushppratap67@gmail.com

**ABSTRACT**

The most communal cancer-related cause of fatality in women in emerging nations is cervical cancer (CC). Persistent infection with hr-HPV primarily 16/18 are acknowledged as major risk factor for cervical carcinogenesis. However, the fact that only a small number of women who have morphologic manifestations of HPV infection develop invasive illness suggests the presence of additional variables in the development of CC. Conserved tiny ncRNAs termed as miRNAs, control the genes expression, comprising those intricate in basic living processes and human cancer. MiRNA dysregulation has frequently been linked to CC. Evaluating the miRNAs impacted by the infection process of HPV and the miRNAs that support the growth and upkeep of malignant cervical tumour cells are the main objectives of this study.

**INTRODUCTION**

As per WHO, CC recognized as 4th most common malignancy with approximately 604,127 newly diagnosed cases and 341,831 deaths worldwide (1, 2). Surprisingly, 90% of CC cases occur in low- and middle-income nations (3). In India, 365.71 million women over the age of 15 are thought to be at risk for CC. Approximately 132,000 new cases of CC are diagnosed annually in India, and 74,000 of those cases result in death, making up roughly one-third of all CC deaths worldwide. Indian females have an annual risk of CC of 2.5 percent and n annual risk of CC mortality of 1.4 percent (4).

SCC, which accounts for 70–80% of cases, and AC, which occurs in 10%–25% of cases, are the two clinical subtypes of cervical tumours (5). Malignant adenoma, clear cell carcinoma (CCC), endometrioid carcinoma (EC), PAC, ACC, ASC, and UDC are a few other uncommon cervical tumours that indicate a wide range of histological types. These tumours account for >1% of freshly diagnosed cases (5).

The foremost menace factor for the CC development is persistent infection with HR-HPVs (6). E6 and E7, oncogenic viral proteins, are expressed by HR-HPVs and are accomplished of composing a variety of molecular pathways that may lead to the development of malignant illness. Merely a few females with morphologic manifestation of infection by HR-HPV proceed to invasive illness, despite the fact that HR-HPV infection is a required cause of CC (6). Intraepithelial lesions, which are frequently histologist categorised as CIN grade 1-3, can develop as a result of persistent infections. In 30 years, almost 1/3rd of CIN3 cases progress to invasion (7). CIN1 and CIN2, which usually recur, are thought to be morphologic manifestations of HPV infection, respectively (8). Only a portion of the mechanisms underlying carcinogenesis are known. As a result, more tumour advocate elements must be active. Understanding of these characteristics is essential for initial detection and may aid in more effective CC therapy and prognosis.

The majority of research focuses on the genomic dysregulation of host-cell proteins linked to accelerating cervical tumorigenesis. Exploration has recently focused on ncRNAs, particularly miRNAs and they are small, double-stranded, 19 to 24 nucleotides long and highly conserved (9). They undesirably regulate coding genes expression by forming hybrids with complementary or nearly complementary sequences found in the 3′-UTR of target mRNAs. Such binding specifically prevents translation or promotes mRNA breakdown (10). MiRNAs are crucial regulators of numerous cellular pathways linked to the emergence of cancer because of their roles.

**MIRNA AND CANCER**

The majority of miRNAs play a role in the control of basic processes in biology, including cell cycle (11), apoptosis (12), proliferation (13), inflammation (14), differentiating themselves (15), and immune response (16). MiRNAs perform a wide variety of functions, and when these functions are dysregulated, it has significant effects on cellular outcomes and contributes to the emergence of a variety of diseases, encompassing tumours (17), autoimmune ailments (18), disorders of the brain (19), cardiovascular diseases (20).

**CERVICAL CANCER MIRNA SIGNATURE**

In tumours, aberrant miRNA expression is frequently seen (21). The dysregulated miRNA, comprising the up-regulated and the down-regulated, was associated with ICC development. MiR-21, one of the up-regulated miRNAs, has been linked to the progression of CIN and ICC (22, 23, 24). One of the most frequently expressed miRNAs in mammals, miR-21, has a demonstrated association with several cancers (25). Both E6 and E7 may be responsible for enhanced miR-21 expression. Ras-MeK-ERK pathway, which PTEN tumour suppressor, a target of miR-21, regulates, can feed back on viral E6 and E7 (26). Additionally, the over expressed miRNA in the aetiology of cervical tumorigenesis encompasses miR-9, miR-10a, miR-16, miR-20b, miR-25, miR-27a, miR-31, miR-92a, miR-92b, miR-93, miR-106a, miR-146a, miR-155, miR-185, and miR-196a, miR-200a, and miR-378 (27, 28, 29).

In tissues infected by hr-HPV and CIN2 or CIN3, miR-218 was shown to be the miRNA that was most significantly down regulated (30, 31). Additionally, miR-29a expression diminished in CIN and ICC (32). By inhibiting the CDC42-PAK1 signalling pathway, the miR-29a has been demonstrated to reduce cell migration and proliferation, which protects against CC (33). Additionally, miR-23b, miR-34a, miR-99a, miR-100, miR125b, miR-145, miR193b, miR-203, miR-375, miR-424, and miR-497 have been found to be downregulated in CC (34, 35).

**MIRNA AS A BIOMARKER IN EARLY STAGE FOR CC**

The current gold standard for detecting HPV-associated dysplasia and CC is histopathology and cytology (Pap smear). These techniques are effective and affordable, but they rely largely on interpretation, specimen recollection, technician training, and their sensitivity is only approximately 50% (36). The addition of HPV testing to cervical cytology, which offers 60–70% more protection against ICC than Pap-smear alone, is one of the most recent revisions to cervical cancer screening recommendations (37). However, more perceptive methods are required for prompt and accurate diagnosis. For screening of CC, diagnosis, and follow-up, a liquid biopsy-based approach may theoretically constitute a useful additional (or alternative) paradigm (38). Initial stages of cervical tumorigenesis are typically asymptomatic, and the symptoms of advanced CC are universal and shared by a number of illnesses, necessitating the urgent need for markers that show the presence of CD in the early stages (39). MiRNAs might be thought of as cervical cancer prognostic biomarkers because they are very stable ncRNA species compared to mRNAs and some IncRNAs and have a comparatively high average half-life (5 days on average) (40). Park et al. investigated the prospective clinical significance of specific miRNAs in tissue specimens of cervix and showed the likely of miR-21 and miR-155 in combination with an assay of HPV E6/E7 mRNA as biomarkers for the diagnosis and management of both HPV+ and HPV- LSILs and cervical tumours (41).

**CONCLUSION**

Considering whether miRNA signatures may be linked to present and forthcoming CIN menace in the context of ICC screening may require combining them with additional biomarkers. To decrease CC mortality and achieve successful care, the clinical repercussions of miRNA-based diagnostic as well as therapeutic techniques are essential. Therefore, more research is needed to understand how miRNAs contribute to the development of CC and the mechanisms by which they control cellular processes that promote tumorigenesis. These research may offer sufficient support for the use of miRNAs as CC therapy agents, prognostic biomarkers, and diagnostic biomarkers.

**ABBREVIATIONS**

CC: cervical cancer

ncRNAs: non-coding RNAs

miRNAs: microRNAs

HPV: Human papilloma virus

Hr-HPV: High risk Human papilloma virus

SCC: Squamous cell carcinoma

AC: Adenocarcinoma

CCC: Clear cell carcinoma

EC: Endometrioid carcinoma

PAC: Papillary adenocarcinoma

ACC: Adenoid cystic carcinoma

ASC: Adenosquamous carcinoma

UDC: Undifferentiated carcinoma

CIN: Cervical intraepithelial neoplasia

CD: Cervical dysplasia

**REFERENCES**

1. WHO (2020). Globocan [Online]. Available at: https://gco.iarc.fr/today/data/ factsheets/populations/900-world-fact-sheets.pdf (Accessed July 18, 2021).
2. Pratap PD, Raza ST, Zaidi G, Kunwar S, Ahmad S, Charles MR, Eba A, Rajput M. Genetic Variants in Interleukin-10 Gene Association with Susceptibility and Cervical Cancer Development: A Case Control Study. Glob Med Genet. 2022 Feb 25;9(2):129-140.
3. Cohen P A, Jhingran A, Oaknin A, Denny L.Cervical cancer *Lancet* 2019393(10167):169–182.
4. Pratap P, Raza S T, Zaidi G, Charles M R, Kunwar S. Molecular biology of human papillomavirus, cervical carcinoma and its management. *Canadian J Clin Nutr.*2021;9(01):71–88.
5. Bedell, S. L., Goldstein, L. S., Goldstein, A. R., and Goldstein, A. T. (2020). Cervical Cancer Screening: Past, Present, and Future. Sex. Med. Rev. 8, 28–37.
6. Castellsagué, X. (2008). Natural History and Epidemiology of HPV Infection and Cervical Cancer. Gynecol. Oncol. 110, S4–S7.
7. McCredie MR, Paul C, Sharples KJ, Baranyai J, Medley G, Skegg DC, Jones RW. Consequences in women of participating in a study of the natural history of cervical intraepithelial neoplasia 3. Aust N Z J Obstet Gynaecol. 2010;50(4):363–70.
8. Castle PE, Schiffman M, Wheeler CM, Solomon D. Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2. Obstet Gynecol. 2009;113(1):18–25.
9. Bhaskaran, M., and Mohan, M. (2014). MicroRNAs. Vet. Pathol. 51, 759–774.
10. He, L., and Hannon, G. J. (2004). MicroRNAs: Small RNAs with a Big Role in Gene Regulation. Nat. Rev. Genet. 5, 522–531.
11. Mens, M. M. J., and Ghanbari, M. (2018). Cell Cycle Regulation of Stem Cells by MicroRNAs. Stem Cell Rev Rep 14, 309–322.
12. Taghavipour, M., Sadoughi, F., Mirzaei, H., Yousefi, B., Moazzami, B., Chaichian, S., et al. (2020). Apoptotic Functions of microRNAs in Pathogenesis, Diagnosis, and Treatment of Endometriosis. Cell Biosci 10, 12.
13. Lenkala, D., Lacroix, B., Gamazon, E. R., Geeleher, P., Im, H. K., and Huang, R. S. (2014). The Impact of microRNA Expression on Cellular Proliferation. Hum. Genet. 133, 931–938.
14. Zhou, W., Su, L., Duan, X., Chen, X., Hays, A., Upadhyayula, S., et al. (2018b). MicroRNA-21 Down-Regulates Inflammation and Inhibits Periodontitis. Mol. Immunol. 101, 608–614.
15. Yao, S. (2016). MicroRNA Biogenesis and Their Functions in Regulating Stem Cell Potency and Differentiation. Biol. Proced. Online 18, 8.
16. Chandan, K., Gupta, M., and Sarwat, M. (2020). Role of Host and Pathogen-Derived MicroRNAs in Immune Regulation during Infectious and Inflammatory Diseases. Front. Immunol. 10, 3081.
17. Peng, Y., and Croce, C. M. (2016). The Role of MicroRNAs in Human Cancer. Sig Transduct Target. Ther. 1, 15004.
18. Salvi, V., Gianello, V., Tiberio, L., Sozzani, S., and Bosisio, D. (2019). Cytokine Targeting by miRNAs in Autoimmune Diseases. Front. Immunol. 10, 15.
19. Hussein, M., and Magdy, R. (2021). MicroRNAs in central Nervous System Disorders: Current Advances in Pathogenesis and Treatment. Egypt. J. Neurol. Psychiatry Neurosurg. 57, 36.
20. Zhou, S.-S., Jin, J.-P., Wang, J.-Q., Zhang, Z.-G., Freedman, J. H., Zheng, Y., et al. (2018). miRNAS in Cardiovascular Diseases: Potential Biomarkers, Therapeutic Targets and Challenges. Acta Pharmacol. Sin 39, 1073–1084.
21. Lin S, Gregory RI. MicroRNA biogenesis pathways in cancer. Nat Rev Cancer 2015;15(6):321–33.
22. Deftereos G, Corrie SR, Feng Q, Morihara J, Stern J, Hawes SE, et al. Expression of mir-21 and mir-143 in cervical specimens ranging from histologically normal through to invasive cervical cancer. PLoS One 2011;6(12):e28423.
23. Shishodia G, Shukla S, Srivastava Y, Masaldan S, Mehta S, Bhambhani S, et al. Alterations in microRNAs miR-21 and let-7a correlate with aberrant STAT3 signaling and downstream effects during cervical carcinogenesis. Mol Cancer 2015;14:116.
24. Wilting SM, Snijders PJ, Verlaat W, Jaspers A, van de Wiel MA, van Wieringen WN, et al. Altered microRNA expression associated with chromosomal changes contributes to cervical carcinogenesis. Oncogene 2013;32(1):106–16.
25. Sheedy FJ. Turning 21: induction of miR-21 as a key switch in the inflammatory response. Front Immunol 2015;6:19.
26. Iliopoulos D, Jaeger SA, Hirsch HA, Bulyk ML, Struhl K. STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Mol Cell 2010;39(4):493–506.
27. Gocze K, Gombos K, Kovacs K, Juhasz K, Gocze P, Kiss I. MicroRNA expressions in HPV-induced cervical dysplasia and cancer. Anticancer Res 2015;35(1):523–30.
28. Hu X, Schwarz JK, Lewis JS Jr, Huettner PC, Rader JS, Deasy JO, et al. A microRNA expression signature for cervical cancer prognosis. Cancer Res 2010;70(4):1441–8.
29. Di Leva G, Croce CM. Roles of small RNAs in tumor formation. Trends Mol Med 2010;16(6):257–67.
30. Stokowy T, Eszlinger M, Swierniak M, Fujarewicz K, Jarzab B, Paschke R, et al. Analysis options for high-throughput sequencing in miRNA expression profiling. BMC Res Notes 2014;7: 144.
31. Jimenez-Wences H, Martinez-Carrillo DN, Peralta-Zaragoza O, Campos-Viguri GE, Hernandez-Sotelo D, Jimenez-Lopez MA, et al. Methylation and expression of miRNAs in precancerous lesions and cervical cancer with HPV16 infection. Oncol Rep 2016;35(4):2297–305.
32. Li Y, Wang F, Xu J, Ye F, Shen Y, Zhou J, et al. Progressive miRNA expression profiles in cervical carcinogenesis and identification of HPV-related target genes for miR-29. J Pathol 2011;224(4):484–95.
33. Chen R, Zhang L. MiR-29a inhibits cell proliferation and migration by targeting the CDC42/PAK1 signaling pathway in cervical cancer. Anticancer Drugs 2019;30(6):579–87.
34. Cheung TH, Man KN, Yu MY, Yim SF, Siu NS, Lo KW, et al. Dysregulated microRNAs in the pathogenesis and progression of cervical neoplasm. Cell Cycle 2012;11(15):2876–84.
35. Pereira PM, Marques JP, Soares AR, Carreto L, Santos MA. MicroRNA expression variability in human cervical tissues. PLoS One 2010;5(7):e11780.
36. WHO (2014). “Diagnosis and Treatment of Invasive Cervical Cancer,” in Comprehensive Cervical Cancer Control: A Guide to Essential Practice. Editor W. H. O. 2nd edition.
37. Bedell, S. L., Goldstein, L. S., Goldstein, A. R., and Goldstein, A. T. (2020). Cervical Cancer Screening: Past, Present, and Future. Sex. Med. Rev. 8, 28–37.
38. Palmirotta, R., Lovero, D., Cafforio, P., Felici, C., Mannavola, F., Pellè, E., et al. (2018). Liquid Biopsy of Cancer: a Multimodal Diagnostic Tool in Clinical Oncology. Ther. Adv. Med. Oncol. 10, 1758835918794630.
39. Jia, W., Wu, Y., Zhang, Q., Gao, G., Zhang, C., and Xiang, Y. (2015). Expression Profile of Circulating microRNAs as a Promising Fingerprint for Cervical Cancer Diagnosis and Monitoring. Mol. Clin. Oncol. 3, 851–858.
40. Jiang, Y., Hu, Z., Zuo, Z., Li, Y., Pu, F., Wang, B., et al. (2020). Identification of Circulating MicroRNAs as a Promising Diagnostic Biomarker for Cervical Intraepithelial Neoplasia and Early Cancer: A Meta-Analysis. Biomed. Res. Int. 2020, 4947381.
41. Park, S., Eom, K., Kim, J., Bang, H., Wang, H.-Y., Ahn, S., et al. (2017). MiR-9, miR21, and miR-155 as Potential Biomarkers for HPV Positive and Negative Cervical Cancer. BMC Cancer 17, 658.